JX-99

JX-99 is a potent and highly selective small molecule inhibitor of MAP kinase-interacting serine/threonine-protein kinases 1 and 2 (MNK1/2). These kinases are the sole enzymes responsible for the phosphorylation of eukaryotic initiation factor 4E (eIF4E) at the Ser209 site, a modification that is frequently associated with increased translation of oncogenic mRNAs, including those encoding cyclin D1, c-Myc, and MCL-1. By specifically targeting MNK1/2, JX-99 effectively blocks the phosphorylation of eIF4E without interfering with upstream p38 or ERK signaling pathways. This targeted inhibition leads to the suppression of pro-survival and pro-proliferative protein synthesis, inducing cell cycle arrest and apoptosis in various malignant cell lines. Preclinical research has demonstrated that JX-99 possesses significant anti-tumor activity in models of glioblastoma and acute myeloid leukemia, making it a promising candidate for the treatment of cancers characterized by dysregulated protein translation.